TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03878446
Drug: Somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Somapacitan injected under the skin once a week.
Study: NCT02284984
Drug: Rituximab with belimumab
Normalized name: Belimumab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
Study: NCT01834014
Drug: L-OHP
Normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT01751048
Drug: SE
Normalized name: Ser
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
Study: NCT03703102
Drug: KHK4083
Normalized name: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-OX40 Monoclonal Antibody KHK4083
Study: NCT00039585
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02458963
Drug: Gonadotropin
Normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
Study: NCT00234689
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01041482
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib 400mg twice daily
Study: NCT00428142
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3mg/m2 days 1 \& 8
Study: NCT00428142
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/m2 days 1-5
Study: NCT00428142
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4mg/m2 day 1 (dose capped at 2mg)
Study: NCT01356407
Drug: PICOPREP
DrugBank: Picosulfuric acid (DB09268)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02162836
Drug: JNJ-56021927
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
Study: NCT02111161
Drug: IVIG (Privigen)
Normalized name: Privigen
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of 25 g IVIG (250 ml)
Study: NCT04417036
Drug: BAY1097761 Active Dose 1
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a lower dose ADM by inhalation
Study: NCT04417036
Drug: BAY1097761 Active Dose 2
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a higher dose ADM by inhalation
Study: NCT04585464
Drug: EDG-5506
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDG-5506 is administered orally as a single dose or once daily
Study: NCT01197521
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fostamatinib 100 mg twice daily
Study: NCT01197521
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fostamatinib 100 mg twice daily/150 mg once daily
Study: NCT01197521
Drug: placebo, fostamatinib
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
Study: NCT01245582
Drug: oxaliplatin (SR96669)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:injection~Route of administration: intravenous
Study: NCT01245582
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00405067
Drug: BMS-201038 (AEGR-733)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00405067
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00944424
Drug: Docetaxel + High dose Vitamin D2
Normalized name: vitamin D2
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + High dose Vitamin D2
Study: NCT00944424
Drug: Docetaxel + Standard dose Vitamin D2
Normalized name: vitamin D2
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + Standard dose Vitamin D2
Study: NCT02192203
Drug: Menthol Only Gel
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% menthol
Study: NCT03767075
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg, administered IV, once every 3 weeks
Study: NCT03767075
Drug: Futibatinib
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg administered orally, once daily (QD) continuously in 28-day cycles.
Study: NCT03767075
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Study: NCT03462576
Drug: Emricasan
Normalized name: Emricasan
DrugBank: Emricasan (DB05408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug for NASH treatment in Main Conatus protocol
Study: NCT06385483
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02964078
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
Study: NCT02964078
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
Study: NCT03201458
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03201458
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02092012
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
Study: NCT00433108
Drug: Mitoquinone mesylate (MitoQ)
Normalized name: mesylate
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00300664
Drug: Human Growth hormone
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03962101
Drug: OPC-61815 injection
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
Study: NCT03137368
Drug: Exemestane Tablets
Normalized name: Exemestane Tablets
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug therapy
Study: NCT01834014
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT02817321
Drug: single dose ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed
Study: NCT02817321
Drug: continuously infusion of ropivacaine
Normalized name: Uniphyllin Continus
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose
Study: NCT02817321
Drug: Morphine given as IPCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study: NCT00518154
Drug: Pyridostigmine tablets
Normalized name: pyridostigmine Oral Tablet
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 30mg tid PO for 12 weeks
Study: NCT01468584
Drug: MP-424 (generic name:Telaprevir)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750mg q8h for 12 weeks
Study: NCT01468584
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 - 1000 mg/day based on body weight for 24 weeks
Study: NCT01468584
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5mcg/kg/week for 24 weeks
Study: NCT01536600
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The insulin dose and regimen was individualised at the physician's discretion
Study: NCT03949920
Drug: Migalastat
Normalized name: Migalastat
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
Study: NCT01867281
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03137368
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug therapy
Study: NCT01044771
Drug: change from tenofovir to raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
Study: NCT00431197
Drug: Ketoconazole, Dexamethesone, Androgel,GnRH
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01433497
Drug: Masitinib
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03853785
Drug: Topical Podophyllin
Normalized name: podophyllin Topical Solution
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
Study: NCT00271596
Drug: 20mg daily citalopram
Normalized name: citalopram 20 MG
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
Study: NCT00892385
Drug: Methoxyamine
Normalized name: Methoxyamine
DrugBank: Methoxyamine (DB06328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
Study: NCT00892385
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT03168880
Drug: Paclitaxel + Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
Study: NCT03168880
Drug: Paclitaxel only
Normalized name: Paclitaxel only product
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01816997
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo
Study: NCT00053417
Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)
Study: NCT00053417
Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP)
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)
Study: NCT00053417
Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)
Study: NCT03112863
Drug: Bakuchiol
Normalized name: Bakuchiol
DrugBank: Bakuchiol (DB16102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive bakuchiol
Study: NCT03112863
Drug: Retinol
Normalized name: Retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive retinol
Study: NCT02494479
Drug: Prurisol
Normalized name: chlorhexidine gluconate Mouthwash [Perisol]
DrugBank: Abacavir hydroxyacetate (DB12187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg tablet
Study: NCT01116648
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01116648
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03484819
Drug: Copanlisib Hydrochloride
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03015532
Drug: Bupivicaine HCl
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl without epinephrine
Study: NCT03015532
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine, via injection
Study: NCT04134845
Drug: Dantrolene/Ryanodex
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: muscle relaxant
Study: NCT02184195
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet -100mg
Study: NCT02184195
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet-150mg
Study: NCT02631525
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
Study: NCT02631525
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total intravenous anesthesia based on propofol
Study: NCT03792815
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: busulfan 3.2mg/kg iv on day -8, -7, and -6,
Study: NCT03792815
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 50mg/m2/day i.v. on day -3 and -2
Study: NCT03792815
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: etoposide 400 mg/m2 i.v. on day -5 and -4
Study: NCT00941811
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Local Imiquimod three times weekly for 16 weeks
Study: NCT01708603
Drug: 210 mg brodalumab
Normalized name: brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 210 mg brodalumab administered SC
Study: NCT02354222
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02354222
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT01708603
Drug: 140 mg brodalumab
Normalized name: brodalumab 140 MG/ML
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 140 mg brodalumab administered SC
Study: NCT01708603
Drug: ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
Study: NCT01038661
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV
Study: NCT01038661
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV
Study: NCT03934047
Drug: Tranexamic Acid 100 MG/ML
Normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
Study: NCT03174847
Drug: Mineralocorticoid Receptor Antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Medical treatment with MRA / amiloride
Study: NCT01232647
Drug: Menatetrenone (MK4)
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (MK4) 45 mg daily
Study: NCT02990338
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study: NCT02990338
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT02990338
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Study: NCT03430869
Drug: F-18-THK-5351
Normalized name: THK-5351 F-18
DrugBank: THK-5351 (DB19222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
Study: NCT00748072
Drug: DDAVP
Normalized name: DDAVP
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.3 mcg/kg subcutaneous
Study: NCT00748072
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution 1 ml subcutaneous
Study: NCT03622801
Drug: Iopromide (Ultravist, BAY86-4877)
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
Study: NCT02631772
Drug: Sofosbuvir/Ledipasvir x 12 weeks
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02631772
Drug: Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00725517
Drug: Icodextrin
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
Study: NCT03762369
Drug: CKD-351
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day
Study: NCT03762369
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once a day
Study: NCT03762369
Drug: D930
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: three times a day
Study: NCT02943564
Drug: Rapastinel
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel pre-filled syringes for weekly IV injections.